FOLR1 ( Folate receptor alpha )

ADCs targeting Trop-2, HER2, and FRα have demonstrated notable efficacy in clinical trials, such as Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), which have shown high objective response rates in Trop-2 and HER2-positive patients, respectively. However, ADCs still face challenges regarding resistance and safety, and future efforts must focus on optimizing designs and exploring more emerging targets to achieve the goals of precision medicine. This article provides a focused narrative overview of recent advances in ADCs for the treatment of endometrial cancer, with a primary focus on key targets including Trop-2, HER2, FRα, and Nectin-4.

Moreover, FOLR1 was identified as a potential tumor suppressor and therapeutic target. These findings provide a theoretical basis for senescence-informed molecular stratification and the development of precision treatment strategies in lung adenocarcinoma.

Incorporating histopathological features and biomarkers into routine clinical practice allows for a more accurate estimation of prognosis and a more rational selection of adjuvant therapy. An increasing number of non-anatomical biomarkers are becoming an integral part of the decision-making algorithm in endometrial carcinoma management.

Post-operatively, she received six cycles of carboplatin, paclitaxel, and dostarlimab every three weeks, followed by maintenance dostarlimab. This case illustrates that aggressive multimodal therapy including immune checkpoint inhibition may achieve durable disease control in advanced-stage MMR-deficient uterine LCNEC. While the relative contributions of surgery, chemotherapy, radiation, and immunotherapy cannot be separated, the favorable outcome supports further investigation of immunotherapy in rare high-grade endometrial neuroendocrine carcinomas and underscores the importance of including these histologies in clinical trials.

To our knowledge, no published studies or case reports have yet documented central nervous system activity of mirvetuximab soravtansine in ovarian cancer. This case highlights a potential new therapeutic role for this agent in patients with ovarian cancer and central nervous system involvement and underscores the need for prospective clinical trials to rigorously assess its central nervous system penetration and efficacy in larger patient cohorts.

Mirvetuximab soravtansine (MIRV), which targets folate receptor-1 (FOLR1), is FDA-approved for platinum-resistant tubo-ovarian cancers with ≥75% moderate/strong staining, and emerging studies show meaningful responses to MIRV combination therapy even at lower FOLR1 expression. FOLR1 met current MIRV treatment criteria in one case, while ten others showed expression ranging from 5% to 70%. Although most tumors did not meet current biomarker thresholds for Trastuzumab or MIRV monotherapy, detectable expression supports exploring anti-HER2 T-Dxd and MIRV combination treatments in selected MA/MLA cases.

We report a 65-year-old patient with heavily pretreated, FRα-positive ovarian cancer who developed therapy-related myelodysplastic syndrome with increased blasts (MDS-IB2, DNMT3A-mutated) during therapy with MIRV in combination with carboplatin having received prior PARPi maintenance therapy. This case demonstrates that MIRV can be safely and effectively administered alongside azacitidine, providing clinically meaningful tumor control without compromising hematologic outcomes. These findings support the concurrent management of ovarian cancer and therapy-related MDS as a viable and underutilized treatment approach in a highly challenging clinical setting.

However, considering that three efflux transporters significantly inhibit the placental transport of PS NPs, the transplacental transport capacity of PE NPs was higher than that of PS NPs. The comprehensive binding capacity calculation system proposed in this research offers a new approach to quantitatively assess the risk of NPs placenta exposure and screen for potential toxic microplastics in the placenta.

The results demonstrated significantly higher uptake in CAL51 models compared to MDA-MB-231 models (17.17 ± 2.24%ID/g vs 3.79 ± 1.15%ID/g, P < 0.001), which was further confirmed by subsequent immunohistochemical analysis. In conclusion, 89Zr-DFO-Mirvetuximab holds significant potential for noninvasively identifying TNBC patients with sufficient FRα expression for targeted therapies like Mirvetuximab soravtansine, thereby supporting improved patient stratification and treatment response monitoring.

P2/3, N=860, Recruiting, Daiichi Sankyo | N=344 --> 860

P3, N=466, Recruiting, Incyte Corporation | N=286 --> 466

We first generated a single-chain variable fragment derived from the anti-folate receptor α (FRα) antibody MORAb-003, then we engineered M13 bacteriophage displaying this targeting moiety, enabling high-affinity recognition of FRα-overexpressing ovarian cancer cells...The resulting M13FRα-Ce6-RB conjugates exhibit potent photodynamic activity under both red and green light irradiation, highlighting the potential of refactored M13 phages as flexible nanocarriers for precision phototherapy. This work presents a customizable and translationally relevant nanoplatform for image-guided treatment of chemoresistant ovarian cancer and other FRα-positive malignancies.